SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 28th, 2017 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 3, 2017, between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”).
Re: Letter of Intent for Tender Exchange of Existing Equity SecuritiesAmarantus Bioscience Holdings, Inc. • March 28th, 2017 • Pharmaceutical preparations
This letter agreement sets forth our agreement and understanding as to the essential terms of the tender exchange of certain existing equity securities of Amarantus BioScience Holdings, Inc. (the "Company") located at 315 Montgomery Street, Suite 900, San Francisco, CA 94104, including surrender of all warrants owned by ________ (“Holder”) and a collateral release of assets of the Company, in return for receipt of newly issued equity securities in the Company (“Tender Exchange”) as duly authorized and issued by the Company. The parties intend this letter agreement to be binding and enforceable, and that it will inure to the benefit of the parties and their respective successors and assigns.
CONFIDENTIALAmarantus Bioscience Holdings, Inc. • March 28th, 2017 • Pharmaceutical preparations
This letter agreement sets forth our agreement and understanding as to the essential terms of the tender exchange of certain existing equity securities of Amarantus BioScience Holdings, Inc. (the "Company") located at 315 Montgomery Street, Suite 900, San Francisco, CA 94104, including surrender of all warrants owned by ______ (“Holder”) and a collateral release of assets of the Company, in return for receipt of newly issued equity securities in the Company (“Tender Exchange”) as duly authorized and issued by the Company. The parties intend this letter agreement to be binding and enforceable, and that it will inure to the benefit of the parties and their respective successors and assigns.
CONFIDENTIALAmarantus Bioscience Holdings, Inc. • March 28th, 2017 • Pharmaceutical preparations
This letter agreement, including that certain Addendum of even date thereto include as attached on Exhibit B, sets forth our agreement and understanding as to the essential terms of the tender exchange of existing debt and equity securities of Amarantus BioScience Holdings, Inc. (the "Company") located at 315 Montgomery Street, Suite 900, San Francisco, CA 94104, including surrender of all warrants owned by _____ (“Holder”) and a collateral release of assets of the Company, in return for receipt of newly issued equity securities in the Company (“Tender Exchange”) as duly authorized and issued by the Company. The parties intend this letter agreement to be binding and enforceable, and that it will inure to the benefit of the parties and their respective successors and assigns.
